Know Cancer

forgot password

An Open-Label Pharmacokinetic and Safety Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

Phase 1
18 Years
Not Enrolling
Malignant Melanoma

Thank you

Trial Information

An Open-Label Pharmacokinetic and Safety Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

Group A: Six to 12 subjects will be treated with transfectoma-derived MDX-010 at 2.8 or 5
mg/kg/dose, or with hybridoma-derived MDX-010 at 3 mg/kg/dose administered on Days 1, 57,
and 85. The 2.8, 3, and 5 mg/kg dosage cohorts may be initiated concurrently. Additionally,
6 subjects per cohort will receive single doses of transfectoma-derived MDX-010 at 7.5, 10,
15, and 20 mg/kg.

Dose escalation from the 5 mg/kg cohort to the 7.5 mg/kg cohort will depend on the safety
profile following a single dose of 5 mg/kg. Once all subjects are enrolled in the 5 mg/kg
cohort and 4 weeks have elapsed since the sixth subject in the cohort has received the first
infusion, dose escalation to the 7.5 mg/kg cohort may occur if ≤1 DLT has occurred in the 5
mg/kg cohort. Dose escalation to the 10 mg/kg cohort may occur 4 weeks after the sixth
subject in the 7.5 mg/kg/dose cohort has received the first infusion (with ≤1 DLT). Dose
escalation to the 15 and 20 mg/kg cohorts may occur 4 weeks after the sixth subject in the
previous cohort has received the first infusion (with ≤1 DLT). Up to six additional subjects
may be enrolled in the MTD dose cohort or in the 20 mg/kg dose cohort if MTD is not

Group B: If single-dose administration of MDX-010 at 10 mg/kg is well tolerated (≤1 DLT in
the cohort in Group A), then an additional 12 to 20 subjects will be enrolled and treated
with MDX-010 at 10 mg/kg/dose administered on Days 1, 22, 43, and 64.

Subjects who respond to therapy will be followed until disease progression or a maximum of
approximately 1 year. Subjects with a response of SD ≥ 3 months, PR, or CR to their initial
treatment cycle who subsequently relapse may be eligible for retreatment with the same
regimen or an alternate regimen considered to be more effective at the time of retreatment.

Inclusion Criteria:

- Subject must have read, understood, and provided written informed consent and
authorization in compliance with the Health Insurance Portability and Accountability
Act (HIPAA) afer the nature of the study has been fully explained.

- Subject must be at least 18 years of age with a histologic diagnosis of unresectable
Stage III or IV malignant melanoma (may include mucosal melanoma). Subjects with
either stable or progressive malignancy will be permitted in the study.
Classification of stable or progressive disease, to be recorded for all subjects,
will be defined by the Response Evaluation Criteria in Solid Tumors (RECIST), as
detailed in Appendix 3 and determined since last melanoma treatment. Subjects must
have at least 1 site of measurable disease.

- At least 4 weeks since treatment (surgery, chemotherapy, radiation, or immuno-
therapy) for melanoma and recovered from any serious toxicity experienced during

- Life expectancy of at least 18 weeks.

- Karnofsky Performance Status of at least 70%

- Screening laboratory values must meet the following criteria:

- WBC ≥2500/μL

- ANC ≥1500/μL

- Platelets ≥100 x 10'/μL

- Hematocrit ≥30%

- Hemoglobin ≥10 g/dL

- Creatinine ≤2 mg/dL

- AST ≤2 x ULN*

- Bilirubin ≤1.0 x ULN*, (except subjects with Gilbert's Syndrome, who must have a
total bilirubin less than 3.0 mg/dL)

- HIV negative

- HBsAg negative

- anti-HCV nonreactive. If reactive, subject must have a negative HCV RNA
qualitative PCR.

- Unless definitely attributable to disease.

Exclusion Criteria:

- Any prior malignancy except for the following: adequately treated basal or squamous
cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix, or any
other cancer from which the subject has been disease-free for at least 5 years

- History of autoimmune disease (including uveitis and autoimmune inflammatory eye
disease) prior to entrance into the study.

- Active infection requiring therapy, chronic active HBV or HCV, or confirmed
reactivity with HIV tests.

- Tetanus booster immunization within 2 months of initial screening procedures, or a
history of anaphylaxis or severe local reaction to the tetanus vaccine.

- Pregnant or nursing: it is not known what effect MDX-010 could have on the developing
immune system of the fetus or infant, therefore, exposure in utero or via breast milk
will not be allowed.

- Any underlying medical condition which, in the opinion of the principal investigator,
will make the administration of study drug hazardous or obscure the interpretation of
adverse events.

- Any concurrent medical condition requiring the use of systemic or topical
corticosteroids or the use of immunosuppressive agents (e.g. cyclosporine and its
analog, or chemotherapy agents). All corticosteroid use must have been discontinued
at least 4 weeks prior to trial entry.

- Prior treatment with MDX-010 or any other anti-CTLA-4 monoclonal antibody.

- Evidence or history of significant cardiac, pulmonary, hepatic, renal, psychiatric or
gastrointestinal disease that would make the administration of MDX-010 unsafe.

- Concurrent treatment with chemotherapy or other immunotherapy regimens (must be
completed at least 4 weeks before Screening).

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the safety and pharmacokinetic profile of single and multiple doses of MDX-010.

Outcome Time Frame:

up to approximately 1 year

Safety Issue:


Principal Investigator

Bristol-Myers Squibb

Investigator Role:

Study Director

Investigator Affiliation:

Bristol-Myers Squibb


United States: Institutional Review Board

Study ID:




Start Date:

July 2003

Completion Date:

June 2007

Related Keywords:

  • Malignant Melanoma
  • Melanoma



Arizona Cancer Center Tucson, Arizona  85724
USC/Norris Comprehensive Cancer Center Los Angeles, California  90033-0800
Providence Portland Medical Center Portland, Oregon  97213-3635
Piedmont Oncology Specialists Charlotte, North Carolina  28207